Investor Relations

A leadership story in the field of advanced cell therapy

Day High:
Day Low:
Volume:
on
Copyright West LLC. Minimum 15 minutes delayed.

Investor Relations

Press Releases

May 15, 2019

Vericel to Present at the 2019 UBS Global Healthcare Conference on Wednesday, May 22, 2019

May 7, 2019

Vericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance

May 7, 2019

Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns

Events and Presentations

Stock Quote & Analyst Coverage

Stock Quote ()

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low
Vericel Corporation is covered by the following analysts.
Ryan Zimmerman
BTIG
Jeff Cohen
Ladenburg Thalmann
Danielle Antalffy
LEERINK
Chad Messer
Needham
Kevin DeGeeter
Oppenheimer

Vericel Corporation is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Vericel Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vericel Corporation or its management. Vericel Corporation does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.